What drones and drug discovery have in common

What do weapons and drug discovery have in common? Over the last 24 hours, billions of dollars and a lead investor. In quick succession, Demis Hassabis’s Isomorphic Labs announced it had raised a $2.1 billion Series B, and very early today, Anduril announced it had closed its $5 billion Series H at a $61 billion valuation. (Thrive Capital led in both rounds, and Andreessen Horowitz additionally led for Anduril.) I have an admittedly odd vantage point here: Two of the biggest features of my career to date have involved me spending a lot of time with Anduril and Isomorphic, respectively, a defense tech company and an AI drug discovery company. And though I will under no circumstances tell you they are the same (building drones and searching for cancer cures have wildly different financial and ethical landscapes), they also have a few things in common. Both Anduril and Isomorphic are deeply technical companies that have risen at a time when advances in AI have not only rendered the impossible possible, but made moonshots seem earthbound. Hassabis and Google DeepMind’s AlphaFold, which won the 2024 Nobel Prize, is the foundation of the Isomorphic spinout, proof that AI could make biological vastness legible. Anduril, meanwhile, is building its business on the kind of autonomous weapons and systems that very well would have been out-of-reach twenty years ago. When the numbers are tallied for all the venture dollars flowing into AI, though these billions will count, neither is something I would personally consider “an AI company,” whatever such a phrase means these days. Perhaps the more salient thing Anduril and Isomorphic have in common: Both are at inflection points where, in the coming months and years, results matter more than anything else. “On the Isomorphic side, we care about the outcome,” Hassabis told me yesterday. “First and foremost, it’s about curing diseases or making a breakthrough on a particular property we care about. We don’t care so much about t